Resistance to BRAF-targeted therapy in melanoma

Ryan J. Sullivan(Dana-Farber Cancer Institute), Keith T. Flaherty(Massachusetts General Hospital)

European Journal of Cancer

January 2, 2013

10.1016/j.ejca.2012.11.019

Cited by 370

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

|New England Journal of Medicine|2011|7.7k

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

|Science|2016|5.2k

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

|New England Journal of Medicine|2010|3.5k

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

|Cell|2018|2k

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

|Nature|2010|1.8k